Business

Alvotech Files for US and EU Approval of Adalimumab Biosimilar

November 20th 2020

By Tony Hagen

Article

The rheumatology and gastroenterology biosimilar candidate would enter the lucrative market established by Humira.

Celltrion to Break Ground on Massive New Biopharmaceutical Plant

November 19th 2020

By Tony Hagen

Article

Plans for a $453.3 million high volume plant and research center were unveiled during an industry forum this week in Republic of Korea.

Genentech Files to Block Marketing of Centus' Bevacizumab Biosimilar

November 17th 2020

By Tony Hagen

Article

The reference product rights holder contends that Centus has not provided complete information about its manufacturing processes related to FKB238, the proposed biosimilar.

IGBA Launches Global Biosimilars Week

November 16th 2020

By Tony Hagen

Article

The International Generic and Biosimilar Medicines Association (IGBA) hopes to build momentum for the use of biosimilars.

Prioritize Biosimilar Uptake in Europe, Conference Speaker Says

November 14th 2020

By Skylar Jeremias

Article

In Europe, the pandemic has revealed problems within health care systems and the need to increase access to biosimilars and reform health care policies.

Alvotech and Cipla Partner on 5 Biosimilars for South Africa

November 12th 2020

By Skylar Jeremias

Article

Alvotech and Cipla have joined forces to bring biosimilars to treat oncology and autoimmune diseases to South Africa.

Prestige Biopharma Licenses Trastuzumab Biosimilar to Teva Israel

November 12th 2020

By Skylar Jeremias

Article

Prestige Biopharma and Teva Israel join forces to bring a trastuzumab biosimilar to the Israeli market.

Azar Says Trump's Drug Price Shake-up Is Working

November 11th 2020

By Tony Hagen

Article

HHS Secretary Alex M. Azar said efforts and policies to counter a sharply upward drug price trend have been successful, in a talk with the Association for Accessible Medicine.

Goldman Sachs Bets Large on Biocon Biosimilars

November 9th 2020

By Tony Hagen

Article

Biocon Biologics nets a $150 million investment from Goldman Sachs to further its development and marketing of biosimilars.

Formycon and Bioeq Adjust Submission Strategy for Lucentis Biosimilar

November 9th 2020

By Skylar Jeremias

Article

Formycon and Bioeq say resubmission of the biologics license application for their ranibizumab candidate will not affect launch timing in US or European markets.